Allergen peptide immunotherapy in humans inhibits allergen-induced proliferation of CD4+ T cells but does not affect suppressive activity of CD4+CD25+ T cells

RationaleOur group has previously described immunotherapy using short peptides derived from the major cat allergen Fel d 1, to target CD4+ T cell activation without cross linking IgE. We previously reported that this treatment inhibited allergen late responses, and peripheral blood T cell activation, with increased IL-10 secretion in vitro, and infiltration of CD25+ T cells into allergen challenged skin. In addition we have demonstrated reduced …